Status:
UNKNOWN
Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Macular Degeneration
Visual Acuity
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of the investigators study is to look at the visual outcomes of Ranibizumab injections in combination with photodynamic therapy for the treatment of neovascular age-related macular degener...
Detailed Description
The main cause of severe vision loss in patients with age-related macular degeneration (AMD) is the development of choroidal neovascularization (CNV). This debilitating form of AMD affects the macula ...
Eligibility Criteria
Inclusion
- diagnosed with any subtype of primary subfoveal or juxtafoveal choroidal neovascularization
- must be 50 years of age or older
- have a lesion whose total size is no more than 5400micrometres in greatest linear dimension in the study eye
- CNV that is more than 50% obscured by blood
- have best corrected visual acuity of 20/50-20/320 (Snellen equivalent)
- have been assessed with the use of early treatment diabetic retinopathy study charts
Exclusion
- previous treatment (including verteporfin therapy) that could compromise an assessment of the study treatment
- any permanent structural damage to the central fovea
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00813891
Start Date
January 1 2009
End Date
December 1 2009
Last Update
December 23 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Victoria Hospital and the Montreal Retinal Institute
Montreal, Quebec, Canada, H3Z 1P4